- Price
- $85.28
- Day
- +1.96%
- Mkt Cap
- $798.20M
- 52W Range
- $50.23 – $100.00
- Volume
- 150.1K
- Beta
- 0.67
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Transcat Holdings: Recent Share Price Weakness Provides A Solid Entry Point
Transcat is rated BUY, leveraging a mission-critical, high-retention calibration services business with strong operating leverage and recurring revenue. TRNS delivered robust Q1 FY27 results: revenue rose 22% YoY, service segment operating income surged 35% YoY, and organic service growth was 13% YoY. The stock trades at a 50% discount to its recent EV/EBITDA peak, despite forward EBITDA growth 70% above the industrial sector median.
Transcat Expands its Biomedical Calibration Channel with the Acquisition of Southeastern Biomedical
ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat Expands its Biomedical Calibration Channel with the Acquisition of Southeastern Biomedical.